Competitive molecular docking approach for predicting estrogen receptor subtype α agonists and antagonists

BMC Bioinformatics

Volumn 15, Issue 11, 2014, Pages

  Ng, Hui Wen ^a   Zhang, Wenqian ^a   Shu, Mao ^a   Luo, Heng ^b   Ge, Weigong ^a   Perkins, Roger ^a   Tong, Weida ^a   Hong, Huixiao ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDERS; BINDING ENERGY; BINS; CONFORMATIONS; INDICATORS (CHEMICAL); LIGANDS; MOLECULAR MODELING; PROTEINS; RISK ASSESSMENT; TRANSCRIPTION;

BINDING AFFINITIES; BIOLOGICAL FUNCTIONS; DNA RESPONSE ELEMENT; ENDOCRINE DISRUPTING CHEMICALS; ENDOCRINE DISRUPTION; INDIRECT INTERACTIONS; REGULATORY AUTHORITIES; SIGNALING PATHWAYS;

ENDOCRINE DISRUPTERS;

ENDOCRINE DISRUPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ANTAGONIST; LIGAND;

AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPUTER SIMULATION; METABOLISM; MOLECULAR DOCKING; PROCEDURES;

COMPUTER SIMULATION; ENDOCRINE DISRUPTORS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ANTAGONISTS; ESTROGENS; LIGANDS; MOLECULAR DOCKING SIMULATION;

EID: 84961588282     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-S11-S4     Document Type: Article

References (69)

1. Hiller-Sturmhofel S, Bartke A: The endocrine system: an overview. Alcohol Health Research World. 1998, 22 (3): 153-164.
2. Iguchi T, Katsu Y: Commonality in Signaling of Endocrine Disruption from Snail to Human. BioScience. 2008, 58 (11): 1061-1067. 10.1641/B581109.
3. Shanle EK, Xu W: Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol. 2011, 24 (1): 6-19. 10.1021/tx100231n.
4. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR, Lee DH, Myers JP, Shioda T, Soto AM, vom Saal FS: Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology. Reprod Toxicol. 2013, 38: 1-15.
5. WHO/IPCS: Global assessment of the state-of-the-science of endocrine disruptors. 2002, World Health Organization/International Program on Chemical Safety. WHO/PCS/EDC/02.2
6. Sellin MK, Snow DD, Schwarz M, Carter BJ, Kolok AS: Agrichemicals in nebraska, USA, watersheds: Occurrence and endocrine effects. Environ Toxicol Chem. 2009, 28 (11): 2443-2448. 10.1897/09-135.1.
7. Bonefeld EC, Long M, Hofmeister MV, Vinggaard AM: Endocrine-Disrupting Potential of Bisphenol A, Bisphenol A Dimethacrylate, 4-n-Nonylphenol, and 4-n-Octylphenol in Vitro: New Data and a Brief Review. Environ Health Perspect. 2007, 115 (Suppl 1): 69-76.
8. Gill WB, Schumacher GF, Bibbo M: Pathological semen and anatomical abnormalities of the genital tract in human male subjects exposed to diethylstilbestrol in utero. J Urology. 1977, 117 (4): 477-480.
9. Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM: Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature. 1995, 375 (6532): 581-585. 10.1038/375581a0.
10. Jobling S, Reynolds T, White R, Parker MG, Sumpter JP: A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Enviro Health Perspect. 1995, 103 (6): 582-587. 10.1289/ehp.95103582.
11. Patisaul HB: Effects of environmental endocrine disruptors and phytoestrogens on the kisspeptin system. Adv Exp Med Biol. 2013, 784: 455-479. 10.1007/978-1-4614-6199-9_21.
12. Birnbaum LS, Fenton SE: Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect. 2003, 111 (4): 389-394.
13. Rubin BS, Soto AM: Bisphenol A: Perinatal exposure and body weight. Mol Cell Endocrinol. 2009, 304 (1-2): 55-62. 10.1016/j.mce.2009.02.023.
14. Vaughan TL, Daling JR, Starzyk PM: Fetal death and maternal occupation. An analysis of birth records in the State of Washington. J Occup Med. 1984, 26 (9): 676-678.
15. Palmer JR, Hatch EE, Rosenberg CL, Hartge P, Kaufman RH, Titus-Ernstoff L, Noller KL, Herbst AL, Rao RS, Troisi R: Risk of breast cancer in women exposed to diethylstilbestrol in utero: prelimiinary results (United States). Canc Causes Control. 2002, 13 (8): 753-758. 10.1023/A:1020254711222.
16. Malone KE: Diethylstilbestrol (DES) and breast cancer. Epidemiol Rev. 1993, 15 (1): 108-109.
17. Piver MS, Lele SB, Baker TR, Sandecki A: Cervical and vaginal cancer detection at a regional diethylstilbestrol (DES) screening clinic. Cancer Detect Prev. 1988, 11 (3-6): 197-202.
18. Verloop J, van Leeuwen FE, Helmerhorst TJ, van Boven HH, Rookus MA: Cancer risk in DES daughters. Canc Causes Control. 2010, 21 (7): 999-1007. 10.1007/s10552-010-9526-5.
19. Noller KL, Fish CR: Diethylstilbestrol usage: Its interesting past, important present, and questionable future. Medical Clin North Am. 1974, 58 (4): 793-810.
20. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC: Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009, 30 (4): 293-342. 10.1210/er.2009-0002.
21. Kortenkamp A, Martin O, Faust M, Evans R, McKinlay R, Orton F, Rosivatz E: State of the art assessment of endocrine disrupters. Final report. 2011, Edited by Environment D-Gft
22. Schug TT, Janesick A, Blumberg B, Heindel JJ: Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol. 2011, 127 (3-5): 204-215. 10.1016/j.jsbmb.2011.08.007.
23. Gray LE: Tiered screening and testing strategy for xenoestrogens and antiandrogens. Toxicol Lett. 1998, 102-103: 677-680.
24. Patlak M: A Testing Deadline for Endocrine Disrupters. Environ Sci Technol. 1996, 30 (12): 540A-544A. 10.1021/es962527a.
25. Ding D, Xu L, Fang H, Hong H, Perkins R, Harris S, Bearden ED, Shi L, Tong W: The EDKB: an established knowledge base for endocrine disrupting chemicals. BMC Bioinformatics. 2010, 11 (Suppl 6): S5-10.1186/1471-2105-11-S6-S5.
26. Shen J, Xu L, Fang H, Richard AM, Bray JD, Judson RS, Zhou G, Colatsky TJ, Aungst JL, Teng C: EADB: an estrogenic activity database for assessing potential endocrine activity. Toxicol Sci. 2013, 135 (2): 277-291. 10.1093/toxsci/kft164.
27. Aranda A, Pascual A: Nuclear hormone receptors and gene expression. Phys Rev. 2001, 81 (3): 1269-1304.
28. Hong H, Tong W, Fang H, Shi L, Xie Q, Wu J, Perkins R, Walker JD, Branham W, Sheehan DM: Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts. Environ Health Perspect. 2002, 110 (1): 29-36.
29. Tong W, Fang H, Hong H, Xie Q, Perkins R, Anson J, Sheehan DM: Regulatory application of SAR/QSAR for priority setting of endocrine disruptors: A perspective. Pure Appl Chem. 2003, 75 (11): 2375-2388.
30. Tong W, Perkins R, Fang H, Hong H, Xie Q, Branham W, Sheehan DM, Anson JF: Development of Quantitative Structure-Activity Relationships (QSARs) and Their Use for Priority Setting in the Testing Strategy of Endocrine Disruptors. Regul Res Perspect. 2002, 1 (3): 1-13.
31. Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins R, Sheehan DM: The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci. 2000, 54 (1): 138-153. 10.1093/toxsci/54.1.138.
32. Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, Burghardt R, Safe S: The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol. 2003, 23 (6): 1843-1855. 10.1128/MCB.23.6.1843-1855.2003.
33. Safe S, Kim K: Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol. 2008, 41 (5): 263-275. 10.1677/JME-08-0103.
34. Lathe R, Kotelevtsev Y: Steroid signaling: Ligand-binding promiscuity, molecular symmetry, and the need for gating. Steroids. 2014, 82c: 14-22.
35. Nettles KW, Bruning JB, Gil G, O'Neill EE, Nowak J, Guo Y, Kim Y, DeSombre ER, Dilis R, Hanson RN: Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO reports. 2007, 8 (6): 563-568. 10.1038/sj.embor.7400963.
36. Pike AC: Lessons learnt from structural studies of the oestrogen receptor. Best Pract Research. 2006, 20 (1): 1-14. 10.1016/j.beem.2005.09.002.
37. Bruning JB, Parent AA, Gil G, Zhao M, Nowak J, Pace MC, Smith CL, Afonine PV, Adams PD, Katzenellenbogen JA: Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol. 2010, 6 (11): 837-843. 10.1038/nchembio.451.
38. Falconer IR, Chapman HF, Moore MR, Ranmuthugala G: Endocrine-disrupting compounds: a review of their challenge to sustainable and safe water supply and water reuse. Environ Toxicol. 2006, 21 (2): 181-191. 10.1002/tox.20172.
39. Birnbaum LS: State of the science of endocrine disruptors. Environ Health Perspect. 2013, 121 (4): A107-10.1289/ehp.1306695.
40. Kitchen DB, Decornez H, Furr JR, Bajorath J: Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004, 3 (11): 935-949. 10.1038/nrd1549.
41. Zhang L, Sedykh A, Tripathi A, Zhu H, Afantitis A, Mouchlis VD, Melagraki G, Rusyn I, Tropsha A: Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. Toxicol Appl Pharmacol. 2013, 272 (1): 67-76. 10.1016/j.taap.2013.04.032.
42. Wolohan P, Reichert DE: CoMFA and docking study of novel estrogen receptor subtype selective ligands. J Comput Aided Mol Des. 2003, 17 (5-6): 313-328.
43. Schapira M, Abagyan R, Totrov M: Nuclear hormone receptor targeted virtual screening. J Med Chem. 2003, 46 (14): 3045-3059. 10.1021/jm0300173.
44. Huang N, Shoichet BK, Irwin JJ: Benchmarking sets for molecular docking. J Med Chem. 2006, 49 (23): 6789-6801. 10.1021/jm0608356.
45. Shi L, Tong W, Fang H, Xie Q, Hong H, Perkins R, Wu J, Tu M, Blair RM, Branham WS: An integrated "4-phase" approach for setting endocrine disruption screening priorities--phase I and II predictions of estrogen receptor binding affinity. SAR QSAR Environ Res. 2002, 13 (1): 69-88. 10.1080/10629360290002235.
46. Tong W, Hong H, Fang H, Xie Q, Perkins R: Decision forest: combining the predictions of multiple independent decision tree models. J Chem Inf Comput Sci. 2003, 43 (2): 525-531. 10.1021/ci020058s.
47. Hong H, Xie Q, Ge W, Qian F, Fang H, Shi L, Su Z, Perkins R, Tong W: Mold(2), molecular descriptors from 2D structures for chemoinformatics and toxicoinformatics. J Chem Inf Model. 2008, 48 (7): 1337-1344. 10.1021/ci800038f.
48. Hong H, Fang H, Xie Q, Perkins R, Sheehan DM, Tong W: Comparative molecular field analysis (CoMFA) model using a large diverse set of natural, synthetic and environmental chemicals for binding to the androgen receptor. SAR QSAR Environ Res. 2003, 14 (5-6): 373-388. 10.1080/10629360310001623962.
49. Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, Xie Q, Perkins R, Owens W, Sheehan DM: Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol. 2003, 16 (10): 1338-1358. 10.1021/tx030011g.
50. Tanenbaum DM, Wang Y, Williams SP, Sigler PB: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA. 1998, 95 (11): 5998-6003. 10.1073/pnas.95.11.5998.
51. Nettles KW, Bruning JB, Gil G, Nowak J, Sharma SK, Hahm JB, Kulp K, Hochberg RB, Zhou H, Katzenellenbogen JA: NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol. 2008, 4 (4): 241-247. 10.1038/nchembio.76.
52. Gangloff M, Ruff M, Eiler S, Duclaud S, Wurtz JM, Moras D: Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J Biol Chem. 2001, 276 (18): 15059-15065. 10.1074/jbc.M009870200.
53. Maestro. Schrödinger, LLC, version 9.7
54. Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R, Felts AK, Halgren TA, Mainz DT, Maple JR: Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem. 2005, 26 (16): 1752-1780. 10.1002/jcc.20292.
55. Greenwood JR, Calkins D, Sullivan AP, Shelley JC: Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comput Aided Mol Des. 2010, 24 (6-7): 591-604. 10.1007/s10822-010-9349-1.
56. Shen J, Zhang W, Fang H, Perkins R, Tong W, Hong H: Homology modeling, molecular docking, and molecular dynamics simulations elucidated alpha-fetoprotein binding modes. BMC Bioinformatics. 2013, 14 (Suppl 14): S6-10.1186/1471-2105-14-S14-S6.
57. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT: Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006, 49 (21): 6177-6196. 10.1021/jm051256o.
58. Ascenzi P, Bocedi A, Marino M: Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med. 2006, 27 (4): 299-402. 10.1016/j.mam.2006.07.001.
59. Sousa SF, Fernandes PA, Ramos MJ: Protein-ligand docking: current status and future challenges. Proteins. 2006, 65 (1): 15-26. 10.1002/prot.21082.
60. Bonvin AMJJ: Flexible protein-protein docking. Curr Opin Struct Biol. 2006, 16 (2): 194-200. 10.1016/j.sbi.2006.02.002.
61. Rosenfeld R, Vajda S, DeLisi C: Flexible docking and design. Annu Rev Biophys Biomol Struct. 1995, 24: 677-700. 10.1146/annurev.bb.24.060195.003333.
62. Blizzard TA, Dininno F, Morgan JD, Chen HY, Wu JY, Kim S, Chan W, Birzin ET, Yang YT, Pai LY: Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers. Bioorg Med Chem Lett. 2005, 15 (1): 107-113. 10.1016/j.bmcl.2004.10.036.
63. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M: Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18 (17): 4608-4618. 10.1093/emboj/18.17.4608.
64. Li MJ, Greenblatt HM, Dym O, Albeck S, Pais A, Pais A Fau, Gunanathan C, Milstein D, Degani H, Sussman JL: Structure of estradiol metal chelate and estrogen receptor complex: the basis for designing a new class of selective estrogen receptor modulators. J Med Chem. 2011, 54 (10): 3575-3580. 10.1021/jm200192y.
65. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998, 95 (7): 927-937. 10.1016/S0092-8674(00)81717-1.
66. Osz J, Brelivet Y, Peluso-Iltis C, Cura V, Eiler S, Ruff M, Bourguet W, Rochel N, Moras D: Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors. Proc Natl Acad Sci USA. 2012, 109 (10): E588-594. 10.1073/pnas.1118192109.
67. Srinivasan S, Nwachukwu JC, Parent AA, Cavett V, Nowak J, Hughes TS, Kojetin DJ, Katzenellenbogen JA, Nettles KW: Ligand-binding dynamics rewire cellular signaling via estrogen receptor-alpha. Nat Chem Biol. 2013, 9 (5): 326-332. 10.1038/nchembio.1214.
68. Delfosse V, Grimaldi M, Pons JL, Boulahtouf A, le Maire A, Cavailles V, Labesse G, Bourguet W, Balaguer P: Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes. Proc Natl Acad Sci USA. 2012, 109 (37): 14930-14935. 10.1073/pnas.1203574109.
69. Li H, Ung CY, Yap CW, Xue Y, Li ZR, Chen YZ: Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. J Mol Graph Model. 2006, 25 (3): 313-323. 10.1016/j.jmgm.2006.01.007.